Gender and Age-Specific Seroprevalence of Human Papillomavirus 16 and 18 in General Population in Tehran, Iran Publisher Pubmed



Aghakhani A¹ ; Mamishi S² ; Sabeti S³ ; Bidarizerehpoosh F³ ; Banifazl M⁴ ; Bavand A¹ ; Ramezani A¹ Show Affiliations
Source: Medical Microbiology and Immunology Published:2017

Abstract

The assessment of the gender and age-specific seroprevalence of human papillomavirus (HPV) is essential for planning of HPV vaccine implementation into the preventive programs. In this study, we aimed to determine the age-specific seroprevalence of HPV-16 and 18 in both males and females in Tehran, Iran. Three hundred and seventy-eight women (10–35 years) and 162 men (10–25 years) from Tehran, Iran, were enrolled. Anti-HPV IgG antibodies against HPV-16 and HPV-18 were detected by ELISA using papillomavirus type 16 and 18 L1-capsids as antigen. HPV-16 antibody was detected in 15.6 and 13.6% of women and men, respectively. Antibody against HPV-18 was found positive in 12.7 and 8% of women and men, respectively. The highest seroprevalence of HPV-16 and 18 were seen in women aged 26–30 years (22.2 and 19.4%, respectively), and the lowest HPV-16 and 18 seropositivity rates were seen in males and females aged 10–15 years (9.3 and 1.9%, respectively). In our cohort of study, in males, both anti-HPV-16 and 18 increased after age 15 years, peaking in men aged 21–25 years. In women, both HPV-16 and 18 seropositivity increased after 15 years, declined at 21–25 years, peaked in women aged 26–30 years and again decreased after 30 years. Our data showed increasing exposure rate to high-risk HPV vaccine types in our studied population over 15 years of age. In order to prevent the HPV-related cancers, implementation of HPV vaccine into the national immunization program in Iran and vaccination of females and males less than 15 years of age are suggested. © 2016, Springer-Verlag Berlin Heidelberg.